BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Pharmacyte Biotech's Expanded Follow-Up Study On Malignant Ascites Fluid Accumulation In Final Stages Of Preparation 1/26/2015
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 1/23/2015
Minerva Neurosciences, Inc. (NERV) Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist For Treatment Of Sleep Disorders Including Primary And Comorbid Insomnia 1/22/2015
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015
Disneyland Measles Outbreak Casts Shadow on Anti-Vaccination Movement 1/21/2015
Tekmira (TKMR) Initiates Phase I Clinical Trial Of TKM-HBV 1/21/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-391 Ointment For Actinic Keratosis In A Phase 1 Clinical Study 1/20/2015
Tobira Therapeutics Inc. Doses First Subject In Phase 1 Clinical Trial Of Cenicriviroc And Pioglitazone 1/20/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/16/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Antibe Therapeutics Inc. (ATE.V) Suspends Its Phase I Clinical Trial Due To Safety Concerns 1/16/2015
Pfizer (PFE)'s Working on Once-a-Year Anti-Cholesterol Shot 1/15/2015
Auspex Pharmaceuticals (ASPX) Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population 1/15/2015
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil 1/14/2015
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015
BioLine Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 1/14/2015
BioMarin (BMRN) Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study Of BMN 190 For Treatment Of CLN2 Disorder, A Form Of Batten Disease 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015
Bellicum Pharmaceuticals, Inc. Announces Successful Dosing Of First Patient Cohort With BPX-501 T Cells Following Haplo-Identical Hematopoietic Stem Cell Transplant 1/13/2015
Auspex Pharmaceuticals (ASPX) Announces Favorable Topline Results From Thorough QT Clinical Trial Of SD-809 1/12/2015
Lipocine Inc. (LPCN) Announces Positive Phase 1b Top-Line Results With LPCN 1107 In Pregnant Women 1/12/2015
Second Genome Advances Lead Microbiome Drug Development Program In Phase I Clinical Trial As A Treatment For Inflammatory Bowel Disease 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
TapImmune Inc. (TPIV) Release: Positive Phase 1 Immune Responses In All Evaluable Ovarian And Breast Cancer Patients Advances Vaccine To Phase 2 Clinical Trials 1/12/2015
Cornerstone Pharmaceuticals, Inc. Initiates Phase I Clinical Trial Of CPI-613 For The Treatment Of Metastatic Colorectal Cancer 1/12/2015
Sorrento Therapeutics, Inc. Provides Status Update On The Cynviloq™ Registrational TRIBECA™ Study 1/12/2015
ProteoTech Is Granted Orphan Drug Designation For Systebryl™ (PTI-110) For The Treatment Of AL Amyloidosis 1/12/2015
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015
FDA Approves Cytori Therapeutics, Inc. (CYTX) U.S. Pivotal Scleroderma Trial 1/12/2015
Alnylam Pharmaceuticals (ALNY) Reports Initial Evidence For Potential Correction Of The Hemophilia Phenotype In Phase 1 Study Of ALN-AT3, A Subcutaneously Administered, Investigational RNAi Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia 1/12/2015
ReVance Therapeutics, Inc. (RVNC) Announces Publication of Positive Results From RT002 Phase 1/2 Study 1/9/2015
Journal Of Cardiovascular Pharmacology Publishes Positive Nonclinical Results Of Proteon Therapeutics, Inc. (PRTO)'s PRT-201 In Peripheral Artery Disease 1/9/2015
SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial And Emergency Use Program Of SAGE-547 In Patients With Super-Refractory Status Epilepticus 1/9/2015
TONIX Pharmaceuticals, Inc. (TNXP) Announces Clinical Progress On Potential Treatment for Headache 1/9/2015
Regen BioPharma Identifies Second Generation Gene Silencing Candidates For Blocking Cancer Stem Cell Gene Target 1/9/2015
CoMentis, Inc. And Anvyl Announce The Initiation Of Clinical Trials For APN1125 For The Treatment Of Schizophrenia 1/9/2015
BEAT BioTherapeutics dATP Technology Improves Cardiac Function In End Stage Human Heart Failure Cardiac Muscle 1/9/2015
TRACON Pharmaceuticals, Inc. Announces Results From A Clinical Trial Of TRC105 In Patients With Hepatocellular Carcinoma To Be Presented At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Interim Data From Phase 1/2 Clinical Trial Of PRX-102 For The Treatment Of Fabry Disease 1/8/2015
Karyopharm Therapeutics (KPTI) Announces Orphan Designation Granted By FDA For Selinexor (KPT-330) In Multiple Myeloma 1/8/2015
First Patient Successfully Transplanted With Cryopreserved (Frozen) Nicord® In Gamida Cell Ltd.'s Ongoing Phase I/II Clinical Trial For Blood Cancers 1/8/2015
Cleave Biosciences Initiates Phase 1 Clinical Trial Of CB-5083 In Patients With Advanced Solid Tumors 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01 1/8/2015
Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases 1/8/2015
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Positive Results From Phase 1b Clinical Trial Evaluating APD334 For The Treatment Of Autoimmune Diseases 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Cortice Biosciences Announces Enrollment Of A Phase 1 Trial Evaluating TPI 287 Plus Radiotherapy For Treatment Of Lung And Breast Cancer Metastases To The Brain 1/7/2015
Johnson & Johnson (JNJ) Starts Ebola Vaccine Testing in Humans 1/6/2015
Johnson & Johnson (JNJ) Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen 1/6/2015
GliaCure Completes Phase 1a Clinical Trial In Alzheimer's Disease 1/6/2015
Celsion Corporation (CLSN) Submits DNA-Based Immunotherapy Clinical Protocol To The FDA As Part Of A First Line Treatment For Ovarian Cancer 1/6/2015
Inovio Pharmaceuticals (INO) HIV Immunotherapy Shows Characteristics Considered Vital To Treating HIV 1/6/2015
cCAM Biotherapeutics Receives FDA Approval To Initiate Phase 1 Trial For CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 1/6/2015
Bavarian Nordic (BAVA.CO) Announces Initiation Of Phase 1 Clinical Trial For The Ebola Vaccine Regimen Of MVA-BN® Filo And Janssen's AdVac® technology 1/6/2015
BioLineRx Ltd. Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment 1/6/2015
Cleveland Biolabs Inc. (CBLI) And Incuron Announce Updates On Clinical Progress With Curaxin CBL0137 1/6/2015
Anavex Life Sciences Corp. (AVXL.OB) Encouraged by Scientific Data Confirming Sigma-1 Receptor's Beneficial Direct Interaction With Cannabinoid Receptor 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Merck & Co. (MRK), NewLink Genetics Ebola Vaccine Trial Resumes in Geneva 1/5/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
OncoMed Pharmaceuticals, Inc. (OMED) Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody 1/5/2015
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application To Initiate A Phase 1 Study For ALN-AS1, A Subcutaneously Administered, Investigational Rnai Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias 1/5/2015
Tekmira (TKMR) Provides Update On TKM-PLK1 Phase I/II Clinical Study In Patients With Advanced Gastrointestinal Neuroendocrine Tumors And Adrenocortical Carcinoma 12/31/2014
Idera Pharmaceuticals, Inc. (IDRA) Provides Key Updates On Clinical Development Of IMO-8400 For Treatment Of Waldenstrom's Macroglobulinemia 12/30/2014
Synthetic Biologics, Inc. (SYN) Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/30/2014
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-361 In A Phase 1 Clinical Study 12/24/2014
Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke 12/24/2014
Mirati Therapeutics  (MRTX) Doses First Patient In Expansion Cohorts Of Phase 1b Trial Of MGCD265 In Genetically Selected Patients 12/23/2014
Helix Biopharma (TSX:HBP) Announces Initiation Of First Clinical Site For US Study 12/23/2014
Tekmira (TKMR) Receives Clearance To Conduct A Phase I Clinical Study With TKM-HBV 12/22/2014
New Published Data Show Pluristem Therapeutics (PSTI)'s PLX Cells Protect Neurons 12/22/2014
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1a Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/22/2014
Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use Of Dermal Sheath Cup Cells To Treat Pattern Baldness 12/22/2014
Relmada Therapeutics Doses First Cohort Of Subjects In Human Clinical Trial Of D-Methadone 12/22/2014
AGA's GERD Registry Enrolls First Patients 12/22/2014
ContraFect Corporation (CFRXU) Receives FDA Approval to Initiate Clinical Trials of CF-301 for MRSA Bloodstream Infections 12/22/2014
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors 12/17/2014
Clementia Initiates First Prospective Natural History Study In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 12/17/2014
Capstone Therapeutics (CAPS) Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 12/16/2014
TetraLogic Pharmaceuticals (TLOG) Provides Update On Ovarian Cancer Study 12/16/2014
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis 12/16/2014
Alla Chem Completes Phase Ib/Iia Clinical Study With AV4025, An HCV NS5A Inhibitor 12/16/2014
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase 1 Clinical Trial Of BCX4430 For The Treatment Of Hemorrhagic Fever Viruses 12/15/2014
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma 12/15/2014
Alkermes plc (ALKS) Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia 12/15/2014
Complexa Initiates Phase 1B Study Of CXA-10 In Acute Kidney Injury 12/15/2014
Immunomedics, Inc. (IMMU) Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer 12/12/2014
Synta Pharmaceuticals (SNTA) Announces Presentation Of Results From An Investigator-Sponsored Phase 1 Trial Of Ganetespib In HER2+ Metastatic Breast Cancer At The 2014 San Antonio Breast Cancer Symposium 12/12/2014
Oncothyreon Inc. (ONTY) Announces Presentation Of Positive ONT-380 Data At San Antonio Breast Cancer Symposium 12/12/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Sorafenib In Advanced Hepatocellular Carcinoma 12/11/2014
Calithera Biosciences, Inc. (CALA) Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition In Tumor Biopsy Samples From Patients Treated With CB-839 12/11/2014
Vical Incorporated (VICL) Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial 12/11/2014
Radius (RDUS) Presents RAD1901 Data At 2014 San Antonio Breast Cancer Symposium 12/11/2014
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014
Atterocor Expands Phase 1 Trial Of ATR-101 To Additional Leading Adrenal Cancer Centers 12/11/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Arno Therapeutics Doses First Patient In Expansion Stage Of Modified Phase 1/2 Trial Evaluating Onapristone In Progesterone Receptor Positive Tumors 12/10/2014
ARCA biopharma Receives FDA Orphan Drug Designation For rNAPc2 As A Potential Treatment For Ebola 12/10/2014
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014
Omni Bio Pharmaceutical Announces Encouraging Clinical Data For Use Of Alpha-1 Antitrypsin (AAT) In Steroid-Resistant Graft Versus Host Disease 12/10/2014
Alizé Pharma Announces Positive Results For AZP-531, Its Unacylated Ghrelin Analog, From Two Phase I Clinical Trials In Healthy Volunteers And Obese Subjects 12/10/2014
Can-Fite BioPharma (CFBI) To Initiate The Development Program Of Its Next Generation Drug Cf602 12/9/2014
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide For Acute And Chronic Pain In Phase 1a / 1b Trial 12/9/2014
Seattle Children's Research Institute's Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate In Children With Relapsed Leukemia 12/9/2014
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Cancer Patients 12/9/2014
bluebird bio (BLUE) Announces Data Demonstrating First Four Patients With ß-Thalassemia Major Treated With LentiGlobin® Are Transfusion-Free 12/9/2014
Agios Pharmaceuticals (AGIO) Reports Positive Phase 1 Data In Healthy Volunteers For AG-348, A First-In-Class Investigational Medicine That Targets The Underlying Cause Of Pyruvate Kinase (PK) Deficiency 12/9/2014
Seattle Genetics, Inc. (SGEN) Presents Data From Novel Antibody-Drug Conjugate SGN-CD33A At American Society of Hematology Annual Meeting 12/9/2014
Calithera Biosciences, Inc. (CALA) Presents Preclinical Study Findings For CB-839 At The 56th American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014
Idera Pharmaceuticals, Inc. (IDRA) Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual American Society of Hematology Meeting 12/9/2014
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma 12/9/2014
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide JZP-386 Program Update 12/9/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Results For ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders, From Ongoing Phase 1 Trial 12/9/2014
Sevion Therapeutics Presents Results Of SNS01-T Phase 1b/2a Dose Escalation Study At American Society of Hematology Annual Meeting 12/9/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society of Hematology Annual Meeting 12/9/2014
Juno Therapeutics’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes In Clinical Trials In Patients With B-Cell Cancers 12/9/2014
Epizyme (EPZM) DOT1L Inhibitor EPZ-5676 Shows Clinical And Biological Activity In Adult Patients With Acute Leukemias In Phase 1 Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Follow-Up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014
Cornerstone Pharmaceuticals, Inc. Commences Phase I Clinical Trial Of CPI-613 For The Treatment Of B-Cell Non-Hodgkin Lymphoma 12/8/2014
Cellerant Therapeutics, Inc. To Present Phase 1 Clinical Data On Evaluation Of CLT-008 In Patients With Acute Myeloid Leukemia At The 2014 American Society of Hematology Annual Meeting 12/8/2014
Agios Pharmaceuticals (AGIO) Announces New Data From Ongoing Phase 1 Trial Of AG-221 Showing Robust Clinical Activity In Patients With Advanced Hematologic Malignancies 12/8/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial Of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, In Elderly 12/8/2014
Affimed Therapeutics AG (AFMD) Presents Final Data For AFM13 Phase 1 Trial At American Society of Hematology 12/8/2014
NKT Therapeutics Inc. Presents Data On Its Therapeutic Program Targeting Sickle Cell Disease At The American Society of Hematology 12/8/2014
Henry Ford Hospital Recruiting Patients For Clinical Trial Which Showed Promising Overall Survival In Recurrent Brain Cancer Patients 12/8/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society of Hematology Annual Meeting 12/8/2014
Seattle Genetics, Inc. (SGEN) Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations In Frontline And Salvage Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application (CTA) For ALN-CC5, An Rnai Therapeutic Targeting Complement C5 In Development For The Treatment Of Complement-Mediated Diseases 12/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Reverses Anticoagulant Effects Of Dabigatran (PRADAXA) In Middle-Aged, Elderly And Renally Impaired Volunteers 12/8/2014
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology 12/8/2014
Seattle Genetics, Inc. (SGEN) Presents Data From SGN-CD19A Antibody-Drug Conjugate At American Society of Hematology Annual Meeting 12/8/2014
Triphase Accelerator Announces Its Proteasome Inhibitor Marizomib Demonstrates Potent Synergistic Anti-Multiple Myeloma Activity In Combination With Pomalidomide 12/8/2014
Bristol-Myers Squibb Company (BMY) Release: Opdivo (nivolumab) Demonstrates High Overall Response Rate Of 87% for Treatment Of Relapsed Or Refractory Hodgkin Lymphoma 12/8/2014
ImmunoGen, Inc. (IMGN) Announces Encouraging IMGN529 Clinical Data Presented At 56th American Society of Hematology Annual Meeting and Exposition 12/8/2014
Cellular Biomedicine Group (CBMG) Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin(TM) Treatment Of Knee Osteoarthritis (KOA) 12/5/2014
OncoSec Medical Inc. Reports ImmunoPulse May Prolong Survival Based On Analysis Of Long-Term Survival Data From Phase I Study In Melanoma 12/5/2014
Five Prime Therapeutics, Inc. (FPRX) Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144 In Gastric Cancer 12/5/2014
Bavarian Nordic (BAVA.CO) Announces First Subject Dosed With Mva-Bn Filo In A Phase 1 Study Investigating A New Prime-Boost Regimen Of Ebola Candidate Vaccines 12/4/2014
University of Michigan To Study GlycoMimetics, Inc. (GLYC)’ GMI-1271 As Potential Treatment For Serious Blood-Clotting Disorder 12/4/2014
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014
Set Point Medical Announces First Trial Of Bioelectronic Therapy To Treat Crohn’s Disease 12/4/2014
Cara Therapeutics, Inc. (CARA) Announces Positive Top-Line Results From Phase 1a / 1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain 12/3/2014
Rhizen Pharmaceuticals S.A. To Present Phase 1 Clinical And Additional Preclinical Data Of RP6530 (Dual PI3K Delta/Gamma Inhibitor) In Hematological Malignancies 12/3/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Nab-Paclitaxel And Gemcitabine In Advanced Pancreatic Cancer 12/3/2014
Syntethic Biologics, Inc. Announces First Patient Dosed In Phase 1a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/2/2014
CollPlant Launched A Clinical Trial With VergenixFG; A Gel Based On A Human Collagen For The Treatment Of Chronic Wounds 12/2/2014
AstraZeneca PLC (AZN) And Eli Lilly (LLY) Move Alzheimer's Drug Into Big Trial 12/1/2014
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Ampio Pharmaceuticals, Inc. (AMPE) Announces Results Of The Open Label Portion Of The Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Osteoarthritis Of The Knee At Week Twenty Of The Trial 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014
Unum Therapeutics Announces Start Of First Phase I Clinical Trial Of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia And Non-Hodgkin Lymphoma 12/1/2014
Data Published By Researchers From Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity Through Previously Unidentified Mechanism 12/1/2014
ABIVAX Successfully Completes First-In-Man Study Of ABX464, A Highly Differentiated Small Molecule Targeting HIV 12/1/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014